Clinical Trial Update: The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating PegIFN alfa optimization in HBeAg-negative chronic hepatitis B patients with low level HBsAg; status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• PegIFN Alfa (pegylated interferon alfa)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Chronic Hepatitis B | Phase 4 | Status: UNKNOWN